Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03521271
Other study ID # GO 17/307
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 5, 2017
Est. completion date January 26, 2018

Study information

Verified date May 2018
Source Hacettepe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study, determining the factors affecting the hand functions of children with Duchenne Muscular Dystrophy who have lost their independent ambulatory ability and determining the effects on the overall upper extremity performance and quality of life of the determined factors.


Description:

Duchenne Muscular Dystrophy (DMD) is the most common neuromuscular disease seen in childhood. DMD is an X linked recessive disorder. DMD is characterized by complete or partial (<3%) deficiency of the cell membrane protein dystrophin.

Dystrophin deficiency results in a permanent deterioration of muscle fibers. This leads to a progressive decrease in muscle strength and functional abilities. The precise mechanism of how the defect of dystrophin leads to degeneration of muscle fibers remains uncertain, but cytoskeletal deterioration, sarcolemmal instability and abnormal calcium homeostasis are thought to play a role in this degeneration.

These patients have symptoms such as limb proximals and progressive muscle weakness in the trunk, gait abnormalities, Gower's sign, various degrees of restriction in daily living activities, and frequent falls. The majority of patients have elevated serum creatine kinase or elevated liver transaminases and less frequently language or general developmental retardation.

Walking ability of this children begins to deteriorate between the ages of 3-6. These patients are generally dependent on wheelchair aged 10-12 years. The loss of walking is the milestone in terms of the progression of the disease. The use of electric wheelchairs limits arm functions such as lengthening and lifting during the late phase of the illness (when the ambulance has been lost and the ambulance is being continued with the wheelchair).

Patients with DMD have an average life span of 30 years with spinal surgery and ventilation support. They spend most of their lives dependent on the wheelchair and need functional use of the upper limbs to maintain the best possible level of independence in their daily life activities throughout their lifetimes.

Although muscle weakness in the proximal limbs is the first finding of the disease, the influence of upper extremity functions gives symptoms after 8 years of age and has a great influence on the level of independence of DMD patients in life since this process. For this reason, rehabilitation approaches for the protection of upper extremity functions from the early period of the disease are of great importance.Effective interventions are necessary to achieve this goal and these variables must be considered when making clinical decisions.

Patients with adult DMD have been shown to be able to perform important functional activities with limited distal motor function in the late phase of disease, but tend to lose these capacities as muscle strength decreases. For this reason, determining the factors (grip strength, thumb opposition, upper extremity joint range of motion, upper extremity muscle strength, etc.) that may affect hand functions, which is an important component in maintaining upper extremity functioning, and how these factors are related to the general functions of the upper extremity it is crucial that this disease leads to physiotherapy rehabilitation programs to be implemented.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date January 26, 2018
Est. primary completion date January 26, 2018
Accepts healthy volunteers No
Gender Male
Age group 8 Years to 16 Years
Eligibility Inclusion Criteria:

- Having a Duchenne Muscular Dystrophy diagnosis by a practicing physician,

- Between the ages of 8-16 years,

- Having lost ambulation ability,

- Brooke Upper Extremity Functional Classification (1-5)

- To have motivation and co-operation with physiotherapist for evaluations to be made

Exclusion Criteria:

- To maintain the capacity of independent ambulance,

- Having cooperative disorder or serious mental disorder,

- Any spinal and / or upper extremity injuries and / or surgery in the last 6 months,

- Having any systemic disease other than DMD,

- Not volunteering to participate in the study

Study Design


Locations

Country Name City State
Turkey Hacettepe University Ankara Samanpazari/Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brooke Upper Extremity Functional Classification (1-6) Children's functional levels were assessed with Brooke Upper Extremity Functional Classification (BUEFS) and children with a BUEFS score between 1-5 were included in the study.
Starting with arms at sides, can abduct arms in a full circle until they touch above head
Can raise arms above head only by flexing elbow or using accesory muscles
Cannot raise arms above head but can raise a glass of water to mouth (using both hands if necessary)
Can raise hands to mouth but cannot raise a glass of water to mouth
Cannot raise hand to mouth but can use hands to hold pen or pick up pennies from table
Cannot raise hands to mouth and has no useful function of hands
2 minutes
Primary Passive joint range of motion Passive range of motions were assessed with goniometer and recorded limitations. 10 minutes
Primary Upper extremity muscle strength Hand held dynamometer 20 minutes
Primary Thumb opposition Thumb opposition was assessed by Kapandji score (1-10). Score Location achieved
Radial side of the proximal phalanx of the 2nd phalanx
Radial side of the middle phalanx of the 2nd phalanx
Tip of the 2nd phalanx
Tip of the 3th phalanx
Tip of the 4th phalanx
Tip of the 5th phalanx
Distal interphalangeal joint crease of the 5th phalanx
Proximal interphalangeal joint crease of the 5th phalanx
Metacarpophalangeal joint crease of the 5th phalanx
Distal palmar crease
2 minutes
Primary Lateral, tripod, two-point pinch strength Pinchmeter 3 minutes
Primary Performance of the upper extremity Performance of the Upper Limb (PUL) (0-74) is including three dimension:
Shoulder dimension (0-16)
Elbow dimension (0-34)
Distal dimension (0-24)
15 minutes
Primary Hand function ABILHAND-Kids (0-36) 3 minutes
Primary Activity limitations ACTIVLIM (0-36) 3 minutes
Primary Gross grip strength Hand dynamometer 2 minutes
Secondary Quality of life assessment of children (0-100) PedsQL-Child report 5 minutes
Secondary Quality of life assessment of parents (0-100) PedsQL-Parent report 5 minutes
See also
  Status Clinical Trial Phase
Completed NCT05575648 - Dual Task in Duchenne Muscular Dystrophy N/A
Terminated NCT03907072 - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2/Phase 3
Not yet recruiting NCT06450639 - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy Phase 2
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Active, not recruiting NCT04906460 - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) Phase 1/Phase 2
Active, not recruiting NCT02500381 - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) Phase 3
Enrolling by invitation NCT05967351 - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study Phase 3
Recruiting NCT03067831 - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT01834040 - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Phase 1/Phase 2
Completed NCT02246478 - A Study of TAS-205 for Duchenne Muscular Dystrophy Phase 1
Active, not recruiting NCT01772043 - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping N/A
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Completed NCT00758225 - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) Phase 2
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting NCT03513367 - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting NCT05712447 - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT03319030 - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated NCT01753804 - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy. N/A
Completed NCT02530905 - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Phase 1